Verapamil contributes to the clastogenic effects of acrylamide, cyclophosphamide, and dioxidine on somatic cells of BALB/C and C57BL/6 mice

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 440, Issue 2, 1999, Pages 171-179

  Nesterova, Elena V ^a   Durnev, Andrei D ^a   Seredenin, Sergei B ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Acrylamide; Co clastogenic activity; Cyclophosphamide; Dioxidine; Verapamil

Indexed keywords

CLASTOGEN; CYCLOPHOSPHAMIDE; DIOXIDINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; MUTAGENESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ACRYLAMIDE; ANIMALS; BONE MARROW CELLS; CALCIUM CHANNEL BLOCKERS; CHROMOSOME ABERRATIONS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUTAGENS; QUINOXALINES; VERAPAMIL;

ANIMALIA;

EID: 0032945888     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(99)00024-8     Document Type: Article

References (20)

1. Abbaszadegan M.R., Foley N.E., Gleason-Guzman M.C., Dalton W.S. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line. Int. J. Cancer. 66(4):1996;506-514.
2. Adler I.D., Ingwersen I., Kliech U., Tarras A. El Clastogenic effects of acrylamide in mouse bone marrow cells. Mutat. Res. 206:1988;379-385.
3. Anderson D., Bishop J.B., Garner R.C., Ostrosky-Wegman P., Selby P.B. Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat. Res. 330:1995;115-181.
4. Backer L., Dearfield K., Erexson G., Campbell J., Westbrook-Collins B., Allen J. The effects of acrylamide on mouse germ-line and somatic cell chromosomes. Environ. Mol. Mutagen. 13:1989;218-226.
5. Burt V.L., Whelton P., Roccella E.J. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 25:1995;305-315.
6. Chalmers J. The treatment of hypertension. Br. J. Clin. Pharmacol. 42(1):1996;29-35.
7. Chatterjee M., Robson C.N., Harris A.L. Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell strains. Cancer Res. 50(9):1990;2818-2822.
8. Chuman Y., Chen Z.S., Sumizawa T., Furukawa T., Haraguchi M., Takebayashi Y., Niwa K., Yamada K., Aikou T., Akiyama S. Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells. Biochem. Biophys. Res. Commun. 226:1996;158-165.
9. Cihak R., Vontorkova M. Cytogenetic effects of acrylamide in the bone marrow of mice. Mutat. Res. 209:1988;91-94.
10. Coleva M., Benova D. Genotype response to the clastogenic and aneuploid effect of cyclophosphamide. Mutat. Res. 216:1989;303-304.
11. Durnev A.D., Guseva N.V., Sazontova T.G., Pleskovskaya G.N., Seredenin S.B. Genotypic, sex-related, and age-related differences in manifestations of the clastogenic effect of cyclophosphamide in mice. Bull. Exp. Biol. Med. 120(10):1995;387-390. in Russian.
12. Eytan G.D., Regev R., Oren G., Assaraf Y.G. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J. Biol. Chem. 271(22):1996;12897-12902.
13. Russo A., Gabbani G., Simoncini B. Weak genotoxicity of acrylamide on premeiotic and somatic cells of the mouse. Mutat. Res. 309(2):1994;263-272.
14. Scheid W., Weber J., Rottgers U., Traut H. Enhancement of the mutagenicity of anticancer drugs by the calcium antagonists verapamil and fendiline. Arzneimittelforschung. 4(9):1991;901-904.
15. Scheid W., Traut H. Calcium antagonists as amplifiers of the mutagenicity of cytostatic drugs. Wien Med. Wochenschr. 143(19-20):1993;522-526.
16. S.B. Seredenin, A.D. Durnev, Pharmacological Protection of the Genome, Moscow: VINITI, in Russian, 1992, 162 pp.
17. Toffoli G., Simone F., Corona G., Raschack M., Cappelletto B., Gigante M., Boiocchi M. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem. Pharmacol. 50(8):1995;1245-1255.
18. Tsuruo T. Structure and function of P-glycoprotein in antitumor agent resistance; implication for clinical setting. Nippon. Rinsho. 53(10):1995;2604-2611.
19. WHO, (1989) A Manual of Express Tests for Identifying Chemical Mutagens and Carcinogens, in Hygienic Criteria of Environmental Quality, Geneva: World Health Organization (in Russian), Issue 51, pp. 116-117.
20. WHO, (1985) Acrylamide. Environmental Health Criteria 49. World Health Organization, Geneva.